
Prostate Cancer
Latest News
Latest Videos

CME Content
More News

Moving on to their last patient case, expert panelists review the diagnosis and management of a patient with metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.

Experts share their thoughts on sequencing hormonal agents and patient selection for clinical trials.

Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.

A review of recent data from the TheraP trial.

Tanya Dorff, MD, explains safety and efficacy data from the CARD trial.

Michael J. Morris, MD, discusses the results of the VISION trial of 177-lutetium-PSMA-61 in patients with metastatic castration-resistant prostate cancer.

Before closing out their discussion on metastatic CSPC, expert oncologists consider how best to educate patients and address the remaining unmet needs in this setting.

After reviewing data from the ARASENS trial, experts consider the role of the daralutamide-containing triplet regimen in metastatic CSPC.

During a Targeted Oncology case-based roundtable event, Sheela Tejwani, MD, discussed therapy options for a patient with metastatic castration-sensitive prostate cancer.

Adam Weiner, MD, discusses the importance of molecular testing for prostate cancer and what the current targeted therapy landscape looks like for this disease.

During a live virtual event, Roby A. Thomas, MD, discussed the choice of therapy for a patient with metastatic castration-sensitive prostate cancer.

Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.

A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.

Key opinion leaders review the case of a 72-year-old man with metastatic CSPC and consider optimal treatment approaches in this setting.

In the interview, Mark Markowski, MD, discussed how the findings from the phase 1/2 trial of sabizabulin in patients with metastatic castration-resistant prostate cancer this may influence future research with the oral agent.

During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.



































